Skip to main content
Top
Published in: Diabetologia 4/2009

01-04-2009 | Article

Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis

Authors: S. Zraika, R. L. Hull, J. Udayasankar, K. Aston-Mourney, S. L. Subramanian, R. Kisilevsky, W. A. Szarek, S. E. Kahn

Published in: Diabetologia | Issue 4/2009

Login to get access

Abstract

Aims/hypothesis

Islet amyloid in type 2 diabetes contributes to loss of beta cell mass and function. Since islets are susceptible to oxidative stress-induced toxicity, we sought to determine whether islet amyloid formation is associated with induction of oxidative stress.

Methods

Human islet amyloid polypeptide transgenic and non-transgenic mouse islets were cultured for 48 or 144 h with or without the antioxidant N-acetyl-l-cysteine (NAC) or the amyloid inhibitor Congo Red. Amyloid deposition, reactive oxygen species (ROS) production, beta cell apoptosis, and insulin secretion, content and mRNA were measured.

Results

After 48 h, amyloid deposition was associated with increased ROS levels and increased beta cell apoptosis, but no change in insulin secretion, content or mRNA levels. Antioxidant treatment prevented the rise in ROS, but did not prevent amyloid formation or beta cell apoptosis. In contrast, inhibition of amyloid formation prevented the induction of oxidative stress and beta cell apoptosis. After 144 h, amyloid deposition was further increased and was associated with increased ROS levels, increased beta cell apoptosis and decreased insulin content. At this time-point, antioxidant treatment and inhibition of amyloid formation were effective in reducing ROS levels, amyloid formation and beta cell apoptosis. Inhibition of amyloid formation also increased insulin content.

Conclusions/interpretation

Islet amyloid formation induces oxidative stress, which in the short term does not mediate beta cell apoptosis, but in the longer term may feed back to further exacerbate amyloid formation and contribute to beta cell apoptosis.
Literature
1.
go back to reference Westermark P, Wernstedt C, Wilander E, Hayden DW, O’Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84:3881–3885PubMedCrossRef Westermark P, Wernstedt C, Wilander E, Hayden DW, O’Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84:3881–3885PubMedCrossRef
2.
go back to reference Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628–8632PubMedCrossRef Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628–8632PubMedCrossRef
3.
go back to reference Betsholtz C, Christmansson L, Engstrom U et al (1989) Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species. FEBS Lett 251:261–264PubMedCrossRef Betsholtz C, Christmansson L, Engstrom U et al (1989) Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species. FEBS Lett 251:261–264PubMedCrossRef
4.
go back to reference Betsholtz C, Svensson V, Rorsman F et al (1989) Islet amyloid polypeptide (IAPP):cDNA cloning and identification of an amyloidogenic region associated with the species-specific occurrence of age-related diabetes mellitus. Exp Cell Res 183:484–493PubMedCrossRef Betsholtz C, Svensson V, Rorsman F et al (1989) Islet amyloid polypeptide (IAPP):cDNA cloning and identification of an amyloidogenic region associated with the species-specific occurrence of age-related diabetes mellitus. Exp Cell Res 183:484–493PubMedCrossRef
5.
go back to reference Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87:5036–5040PubMedCrossRef Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87:5036–5040PubMedCrossRef
6.
go back to reference Opie E (1901) The relation of diabetes mellitus to lesions of the pancreas: hyaline degeneration of the islets of Langerhans. J Exp Med 5:527–540CrossRefPubMed Opie E (1901) The relation of diabetes mellitus to lesions of the pancreas: hyaline degeneration of the islets of Langerhans. J Exp Med 5:527–540CrossRefPubMed
7.
go back to reference Westermark P (1994) Amyloid and polypeptide hormones: what is their relationship. Amyloid Int J Exp Clin Invest 1:47–60 Westermark P (1994) Amyloid and polypeptide hormones: what is their relationship. Amyloid Int J Exp Clin Invest 1:47–60
8.
go back to reference Verchere CB, D’Alessio DA, Palmiter RD et al (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492–3496PubMedCrossRef Verchere CB, D’Alessio DA, Palmiter RD et al (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492–3496PubMedCrossRef
9.
go back to reference Hull RL, Andrikopoulos S, Verchere CB et al (2003) Increased dietary fat promotes islet amyloid formation and beta-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52:372–379PubMedCrossRef Hull RL, Andrikopoulos S, Verchere CB et al (2003) Increased dietary fat promotes islet amyloid formation and beta-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52:372–379PubMedCrossRef
10.
go back to reference Zraika S, Hull RL, Udayasankar J et al (2007) Glucose- and time-dependence of islet amyloid formation in vitro. Biochem Biophys Res Commun 354:234–239PubMedCrossRef Zraika S, Hull RL, Udayasankar J et al (2007) Glucose- and time-dependence of islet amyloid formation in vitro. Biochem Biophys Res Commun 354:234–239PubMedCrossRef
11.
go back to reference Lorenzo A, Razzaboni B, Weir GC, Yankner BA (1994) Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368:756–760PubMedCrossRef Lorenzo A, Razzaboni B, Weir GC, Yankner BA (1994) Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368:756–760PubMedCrossRef
12.
go back to reference Mirzabekov TA, Lin MC, Kagan BL (1996) Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chem 271:1988–1992PubMedCrossRef Mirzabekov TA, Lin MC, Kagan BL (1996) Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chem 271:1988–1992PubMedCrossRef
13.
go back to reference Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48:491–498PubMedCrossRef Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48:491–498PubMedCrossRef
14.
go back to reference Bai JZ, Saafi EL, Zhang S, Cooper GJ (1999) Role of Ca2+ in apoptosis evoked by human amylin in pancreatic islet beta-cells. Biochem J 343:53–61PubMedCrossRef Bai JZ, Saafi EL, Zhang S, Cooper GJ (1999) Role of Ca2+ in apoptosis evoked by human amylin in pancreatic islet beta-cells. Biochem J 343:53–61PubMedCrossRef
15.
go back to reference Anguiano M, Nowak RJ, Lansbury PT Jr (2002) Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41:11338–11343PubMedCrossRef Anguiano M, Nowak RJ, Lansbury PT Jr (2002) Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41:11338–11343PubMedCrossRef
16.
go back to reference Janson J, Soeller WC, Roche PC et al (1996) Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:7283–7288PubMedCrossRef Janson J, Soeller WC, Roche PC et al (1996) Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:7283–7288PubMedCrossRef
17.
go back to reference Konarkowska B, Aitken JF, Kistler J, Zhang S, Cooper GJ (2006) The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells. Febs J 273:3614–3624PubMedCrossRef Konarkowska B, Aitken JF, Kistler J, Zhang S, Cooper GJ (2006) The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells. Febs J 273:3614–3624PubMedCrossRef
18.
go back to reference Meier JJ, Kayed R, Lin CY et al (2006) Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. Am J Physiol Endocrinol Metab 291:E1317–E1324PubMedCrossRef Meier JJ, Kayed R, Lin CY et al (2006) Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. Am J Physiol Endocrinol Metab 291:E1317–E1324PubMedCrossRef
19.
go back to reference Westermark P, Wilander E (1978) The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15:417–421PubMedCrossRef Westermark P, Wilander E (1978) The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15:417–421PubMedCrossRef
20.
go back to reference Clark A, Wells CA, Buley ID et al (1988) Islet amyloid, increased A-cells, reduced B cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9:151–159PubMed Clark A, Wells CA, Buley ID et al (1988) Islet amyloid, increased A-cells, reduced B cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9:151–159PubMed
21.
go back to reference Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110PubMedCrossRef Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110PubMedCrossRef
22.
go back to reference Robertson RP, Harmon JS (2006) Diabetes, glucose toxicity, and oxidative stress: a case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med 41:177–184PubMedCrossRef Robertson RP, Harmon JS (2006) Diabetes, glucose toxicity, and oxidative stress: a case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med 41:177–184PubMedCrossRef
23.
go back to reference Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S (2002) Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 45:85–96PubMedCrossRef Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S (2002) Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 45:85–96PubMedCrossRef
24.
go back to reference Konarkowska B, Aitken JF, Kistler J, Zhang S, Cooper GJ (2005) Thiol reducing compounds prevent human amylin-evoked cytotoxicity. Febs J 272:4949–4959PubMedCrossRef Konarkowska B, Aitken JF, Kistler J, Zhang S, Cooper GJ (2005) Thiol reducing compounds prevent human amylin-evoked cytotoxicity. Febs J 272:4949–4959PubMedCrossRef
25.
go back to reference Janciauskiene S, Ahren B (2000) Fibrillar islet amyloid polypeptide differentially affects oxidative mechanisms and lipoprotein uptake in correlation with cytotoxicity in two insulin-producing cell lines. Biochem Biophys Res Commun 267:619–625PubMedCrossRef Janciauskiene S, Ahren B (2000) Fibrillar islet amyloid polypeptide differentially affects oxidative mechanisms and lipoprotein uptake in correlation with cytotoxicity in two insulin-producing cell lines. Biochem Biophys Res Commun 267:619–625PubMedCrossRef
26.
go back to reference Janciauskiene S, Ahren B (1998) Different sensitivity to the cytotoxic action of IAPP fibrils in two insulin-producing cell lines, HIT-T15 and RINm5F cells. Biochem Biophys Res Commun 251:888–893PubMedCrossRef Janciauskiene S, Ahren B (1998) Different sensitivity to the cytotoxic action of IAPP fibrils in two insulin-producing cell lines, HIT-T15 and RINm5F cells. Biochem Biophys Res Commun 251:888–893PubMedCrossRef
27.
go back to reference Schubert D, Behl C, Lesley R et al (1995) Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci USA 92:1989–1993PubMedCrossRef Schubert D, Behl C, Lesley R et al (1995) Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci USA 92:1989–1993PubMedCrossRef
28.
go back to reference Tucker HM, Rydel RE, Wright S, Estus S (1998) Human amylin induces “apoptotic” pattern of gene expression concomitant with cortical neuronal apoptosis. J Neurochem 71:506–516PubMedCrossRef Tucker HM, Rydel RE, Wright S, Estus S (1998) Human amylin induces “apoptotic” pattern of gene expression concomitant with cortical neuronal apoptosis. J Neurochem 71:506–516PubMedCrossRef
29.
go back to reference D’Alessio DA, Verchere CB, Kahn SE et al (1994) Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 43:1457–1461PubMedCrossRef D’Alessio DA, Verchere CB, Kahn SE et al (1994) Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 43:1457–1461PubMedCrossRef
30.
go back to reference Andrikopoulos S, Verchere CB, Terauchi Y, Kadowaki T, Kahn SE (2000) Beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. Diabetes 49:2056–2062PubMedCrossRef Andrikopoulos S, Verchere CB, Terauchi Y, Kadowaki T, Kahn SE (2000) Beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. Diabetes 49:2056–2062PubMedCrossRef
31.
go back to reference Zraika S, Dunlop M, Proietto J, Andrikopoulos S (2002) The hexosamine biosynthesis pathway regulates insulin secretion via protein glycosylation in mouse islets. Arch Biochem Biophys 405:275–279PubMedCrossRef Zraika S, Dunlop M, Proietto J, Andrikopoulos S (2002) The hexosamine biosynthesis pathway regulates insulin secretion via protein glycosylation in mouse islets. Arch Biochem Biophys 405:275–279PubMedCrossRef
32.
go back to reference Hull RL, Zraika S, Udayasankar J et al (2007) Inhibition of glycosaminoglycan synthesis and protein glycosylation with WAS-406 and azaserine result in reduced islet amyloid formation in vitro. Am J Physiol Cell Physiol 293:C1586–C1593PubMedCrossRef Hull RL, Zraika S, Udayasankar J et al (2007) Inhibition of glycosaminoglycan synthesis and protein glycosylation with WAS-406 and azaserine result in reduced islet amyloid formation in vitro. Am J Physiol Cell Physiol 293:C1586–C1593PubMedCrossRef
33.
go back to reference Kisilevsky R, Szarek WA, Ancsin JB et al (2004) Inhibition of amyloid A amyloidogenesis in vivo and in tissue culture by 4-deoxy analogues of peracetylated 2-acetamido-2-deoxy-alpha- and beta-d-glucose: implications for the treatment of various amyloidoses. Am J Pathol 164:2127–2137PubMed Kisilevsky R, Szarek WA, Ancsin JB et al (2004) Inhibition of amyloid A amyloidogenesis in vivo and in tissue culture by 4-deoxy analogues of peracetylated 2-acetamido-2-deoxy-alpha- and beta-d-glucose: implications for the treatment of various amyloidoses. Am J Pathol 164:2127–2137PubMed
34.
go back to reference Aitken JF, Loomes KM, Konarkowska B, Cooper GJ (2003) Suppression by polycyclic compounds of the conversion of human amylin into insoluble amyloid. Biochem J 374:779–784PubMedCrossRef Aitken JF, Loomes KM, Konarkowska B, Cooper GJ (2003) Suppression by polycyclic compounds of the conversion of human amylin into insoluble amyloid. Biochem J 374:779–784PubMedCrossRef
35.
go back to reference Green JD, Goldsbury C, Kistler J, Cooper GJ, Aebi U (2004) Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation. J Biol Chem 279:12206–12212PubMedCrossRef Green JD, Goldsbury C, Kistler J, Cooper GJ, Aebi U (2004) Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation. J Biol Chem 279:12206–12212PubMedCrossRef
36.
go back to reference Li X, Chen H, Epstein PN (2004) Metallothionein protects islets from hypoxia and extends islet graft survival by scavenging most kinds of reactive oxygen species. J Biol Chem 279:765–771PubMedCrossRef Li X, Chen H, Epstein PN (2004) Metallothionein protects islets from hypoxia and extends islet graft survival by scavenging most kinds of reactive oxygen species. J Biol Chem 279:765–771PubMedCrossRef
37.
go back to reference Scaglia L, Cahill CJ, Finegood DT, Bonner-Weir S (1997) Apoptosis participates in the remodeling of the endocrine pancreas in the neonatal rat. Endocrinology 138:1736–1741PubMedCrossRef Scaglia L, Cahill CJ, Finegood DT, Bonner-Weir S (1997) Apoptosis participates in the remodeling of the endocrine pancreas in the neonatal rat. Endocrinology 138:1736–1741PubMedCrossRef
38.
go back to reference Wang F, Hull RL, Vidal J, Cnop M, Kahn SE (2001) Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50:2514–2520PubMedCrossRef Wang F, Hull RL, Vidal J, Cnop M, Kahn SE (2001) Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50:2514–2520PubMedCrossRef
39.
go back to reference Zraika S, Hull RL, Udayasankar J et al (2007) Identification of the amyloid-degrading enzyme neprilysin in mouse islets and potential role in islet amyloidogenesis. Diabetes 56:304–310PubMedCrossRef Zraika S, Hull RL, Udayasankar J et al (2007) Identification of the amyloid-degrading enzyme neprilysin in mouse islets and potential role in islet amyloidogenesis. Diabetes 56:304–310PubMedCrossRef
40.
go back to reference Chen H, Li X, Epstein PN (2005) MnSOD and catalase transgenes demonstrate that protection of islets from oxidative stress does not alter cytokine toxicity. Diabetes 54:1437–1446PubMedCrossRef Chen H, Li X, Epstein PN (2005) MnSOD and catalase transgenes demonstrate that protection of islets from oxidative stress does not alter cytokine toxicity. Diabetes 54:1437–1446PubMedCrossRef
41.
go back to reference Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME (2004) Improved islet morphology after blockade of the renin–angiotensin system in the ZDF rat. Diabetes 53:989–997PubMedCrossRef Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME (2004) Improved islet morphology after blockade of the renin–angiotensin system in the ZDF rat. Diabetes 53:989–997PubMedCrossRef
42.
go back to reference Leuner K, Hauptmann S, Abdel-Kader R et al (2007) Mitochondrial dysfunction: the first domino in brain aging and Alzheimer’s disease. Antioxid Redox Signal 9:1659–1675PubMedCrossRef Leuner K, Hauptmann S, Abdel-Kader R et al (2007) Mitochondrial dysfunction: the first domino in brain aging and Alzheimer’s disease. Antioxid Redox Signal 9:1659–1675PubMedCrossRef
43.
go back to reference Kaneto H, Kajimoto Y, Miyagawa J et al (1999) Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes 48:2398–2406PubMedCrossRef Kaneto H, Kajimoto Y, Miyagawa J et al (1999) Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes 48:2398–2406PubMedCrossRef
44.
go back to reference Tanaka Y, Gleason CE, Tran PO, Harmon JS, Robertson RP (1999) Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci USA 96:10857–10862PubMedCrossRef Tanaka Y, Gleason CE, Tran PO, Harmon JS, Robertson RP (1999) Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci USA 96:10857–10862PubMedCrossRef
45.
go back to reference Zraika S, Aston-Mourney K, Laybutt DR et al (2006) The influence of genetic background on the induction of oxidative stress and impaired insulin secretion in mouse islets. Diabetologia 49:1254–1263PubMedCrossRef Zraika S, Aston-Mourney K, Laybutt DR et al (2006) The influence of genetic background on the induction of oxidative stress and impaired insulin secretion in mouse islets. Diabetologia 49:1254–1263PubMedCrossRef
46.
go back to reference Kooptiwut S, Kebede M, Zraika S et al (2005) High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction. J Mol Endocrinol 35:39–48PubMedCrossRef Kooptiwut S, Kebede M, Zraika S et al (2005) High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction. J Mol Endocrinol 35:39–48PubMedCrossRef
Metadata
Title
Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis
Authors
S. Zraika
R. L. Hull
J. Udayasankar
K. Aston-Mourney
S. L. Subramanian
R. Kisilevsky
W. A. Szarek
S. E. Kahn
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-008-1255-x

Other articles of this Issue 4/2009

Diabetologia 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.